Donna B Jeffe1,2, Maria Pérez3, Emily F Cole4, Ying Liu5, Mario Schootman6. 1. Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. djeffe@dom.wustl.edu. 2. Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA. djeffe@dom.wustl.edu. 3. Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. 4. Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO, USA. 5. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. 6. College for Public Health and Social Justice, Saint Louis University, St. Louis, MO, USA.
Abstract
BACKGROUND: We examined the effects of surgery type and adjuvant chemotherapy on change in early-stage breast cancer patients' quality of life (QOL) over time. METHODS: A cohort of 549 patients (33.5% ductal carcinoma in situ, 66.5% stages I/IIA) were interviewed a mean 6.1 weeks (Time1), and 6.2 (Time2), 12.3 (Time3), and 24.4 (Time4) months following definitive breast-conserving surgery (BCS) or mastectomy. QOL was measured using the total Functional Assessment of Cancer Therapy-Breast (FACT-B). Adjusting for demographic, psychosocial, and clinical variables, multiple linear regression models estimated the associations between QOL and each of surgery type, chemotherapy, and their 2-way interaction at each interview. Adjusted generalized estimating equation (GEE) models tested Time1-Time4 change in QOL. RESULTS: At Time2, chemotherapy (P < .001) and BCS (P < .001) were independently associated with worse QOL in adjusted linear regression, and the adverse effect of chemotherapy was prominent among patients who received BCS compared with those who received mastectomy (P interaction = .031). In the GEE model, QOL significantly improved over time among patients who received BCS (P trend = .047), mastectomy (P trend = .024), and chemotherapy (P trend < .001), but not among patients who did not receive chemotherapy (P trend = .720). All patients completed adjuvant chemotherapy and radiation by Time3. Regardless of surgery type, patients receiving chemotherapy reported lower QOL following surgery, and QOL improved after completion of adjuvant treatment. CONCLUSIONS: Chemotherapy had a short-term negative impact on QOL after definitive surgical treatment regardless of surgery type. QOL rebounded after completion of adjuvant treatment.
BACKGROUND: We examined the effects of surgery type and adjuvant chemotherapy on change in early-stage breast cancerpatients' quality of life (QOL) over time. METHODS: A cohort of 549 patients (33.5% ductal carcinoma in situ, 66.5% stages I/IIA) were interviewed a mean 6.1 weeks (Time1), and 6.2 (Time2), 12.3 (Time3), and 24.4 (Time4) months following definitive breast-conserving surgery (BCS) or mastectomy. QOL was measured using the total Functional Assessment of Cancer Therapy-Breast (FACT-B). Adjusting for demographic, psychosocial, and clinical variables, multiple linear regression models estimated the associations between QOL and each of surgery type, chemotherapy, and their 2-way interaction at each interview. Adjusted generalized estimating equation (GEE) models tested Time1-Time4 change in QOL. RESULTS: At Time2, chemotherapy (P < .001) and BCS (P < .001) were independently associated with worse QOL in adjusted linear regression, and the adverse effect of chemotherapy was prominent among patients who received BCS compared with those who received mastectomy (P interaction = .031). In the GEE model, QOL significantly improved over time among patients who received BCS (P trend = .047), mastectomy (P trend = .024), and chemotherapy (P trend < .001), but not among patients who did not receive chemotherapy (P trend = .720). All patients completed adjuvant chemotherapy and radiation by Time3. Regardless of surgery type, patients receiving chemotherapy reported lower QOL following surgery, and QOL improved after completion of adjuvant treatment. CONCLUSIONS: Chemotherapy had a short-term negative impact on QOL after definitive surgical treatment regardless of surgery type. QOL rebounded after completion of adjuvant treatment.
Authors: M Amichetti; O Caffo; M Arcicasa; M Roncadin; O Lora; A Rigon; G Zini; L Armaroli; F Coghetto; P Zorat; S Neri; N Teodorani Journal: Breast Cancer Res Treat Date: 1999-03 Impact factor: 4.872
Authors: Amy Trentham-Dietz; Brian L Sprague; Ronald Klein; Barbara E K Klein; Karen J Cruickshanks; Dennis G Fryback; John M Hampton Journal: Breast Cancer Res Treat Date: 2007-08-03 Impact factor: 4.872
Authors: Matthew M Poggi; David N Danforth; Linda C Sciuto; Sharon L Smith; Seth M Steinberg; David J Liewehr; Cynthia Menard; Marc E Lippman; Allen S Lichter; Rosemary M Altemus Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Devon Livingston-Rosanoff; Amy Trentham-Dietz; John M Hampton; Polly A Newcomb; Lee G Wilke Journal: Ann Surg Oncol Date: 2020-02-24 Impact factor: 5.344
Authors: Cathleen Y Xing; Michelle Doose; Bo Qin; Yong Lin; Tiffany L Carson; Jesse J Plascak; Kitaw Demissie; Chi-Chen Hong; Elisa V Bandera; Adana A M Llanos Journal: Breast Cancer Res Treat Date: 2020-09-10 Impact factor: 4.872
Authors: Tess Thompson; Maria Pérez; Yan Yan; Matthew W Kreuter; Julie A Margenthaler; Graham A Colditz; Donna B Jeffe Journal: Soc Sci Med Date: 2020-12-29 Impact factor: 4.634
Authors: H Helbrich; M Braun; C Hanusch; G Mueller; H Falk; R Flondor; N Harbeck; K Hermelink; R Wuerstlein; S Keim; F Neufeld; S Steins-Loeber; K Haertl Journal: Breast Cancer Res Treat Date: 2021-03-31 Impact factor: 4.872
Authors: Elvin T Ng; Russell Z Ang; Bach X Tran; Cyrus S Ho; Zhisong Zhang; Wanqiu Tan; Yu Bai; Min Zhang; Wilson W Tam; Roger C Ho Journal: Int J Environ Res Public Health Date: 2019-12-06 Impact factor: 3.390